Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs (LLY:NYSE)

Core Insights - Innovent Biologics has signed a deal with Eli Lilly to jointly develop experimental medicines targeting cancer and immune-related diseases, marking the continuation of a partnership that has lasted over a decade [4] Company Developments - The new agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, indicating a strong and ongoing relationship in the biopharmaceutical sector [4]